On FDA Critical Path, Device Industry Demands Independence From Pharma
This article was originally published in The Gray Sheet
Executive Summary
AdvaMed objects to FDA's characterization of the device industry's product pipeline as endangered, asserting that the agency's model for determining development timelines is skewed toward drugs